6-methylthiopurine has been researched along with Acute Liver Injury, Drug-Induced in 7 studies
6-methylthiopurine : A thiopurine that is 9H-purine substituted by a methylsulfanyl group at position 6.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective randomized trial in patients with Crohn disease studied whether 6-thioguanine nucleotide (6-TGN) concentration-adapted azathioprine (AZA) therapy is clinically superior to a standard dose of 2." | 9.12 | 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. ( Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2007) |
| "A prospective randomized trial in patients with Crohn disease studied whether 6-thioguanine nucleotide (6-TGN) concentration-adapted azathioprine (AZA) therapy is clinically superior to a standard dose of 2." | 5.12 | 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. ( Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2007) |
| "Thiopurines (azathioprine, 6-mercaptopurine) are a mainstay of treatment in Crohn disease (CD)." | 3.80 | Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease. ( Amre, D; Deslandres, C; Kopylov, U; Seidman, EG; Theoret, Y, 2014) |
| "Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adverse reactions of azathioprine and mercaptopurine in IBD patients, often related to high steady-state 6-methylmercaptopurine ribonucleotide (6-MMPR) metabolite concentrations." | 2.84 | Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. ( Coenen, MJ; de Jong, DJ; Derijks, LJ; Engels, LG; Franke, B; Guchelaar, HJ; Hooymans, PM; Klungel, OH; Scheffer, H; van Marrewijk, CJ; Verbeek, AL; Vermeulen, SH; Wong, DR, 2017) |
| " However, adverse events leading to discontinuation may occur in 10-20% of patients." | 2.71 | 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. ( de Jong, DJ; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Jansen, JB; Mulder, CJ, 2003) |
| " The primary outcome was the occurrence of 6-thioguanine induced hepatotoxicity, scaled according to the Common Terminology Criteria for Adverse Events." | 1.38 | Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. ( de Boer, NK; Mulder, CJ; Seinen, ML; van Asseldonk, DP; van Bodegraven, AA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brackett, J | 1 |
| Schafer, ES | 1 |
| Leung, DH | 1 |
| Bernhardt, MB | 1 |
| Kopylov, U | 1 |
| Amre, D | 1 |
| Theoret, Y | 1 |
| Deslandres, C | 1 |
| Seidman, EG | 1 |
| Wong, DR | 1 |
| Coenen, MJ | 1 |
| Derijks, LJ | 2 |
| Vermeulen, SH | 1 |
| van Marrewijk, CJ | 1 |
| Klungel, OH | 1 |
| Scheffer, H | 1 |
| Franke, B | 1 |
| Guchelaar, HJ | 1 |
| de Jong, DJ | 2 |
| Engels, LG | 2 |
| Verbeek, AL | 1 |
| Hooymans, PM | 2 |
| Gardiner, SJ | 1 |
| Gearry, RB | 1 |
| Burt, MJ | 1 |
| Ding, SL | 1 |
| Barclay, ML | 1 |
| van Asseldonk, DP | 1 |
| Seinen, ML | 1 |
| de Boer, NK | 1 |
| van Bodegraven, AA | 1 |
| Mulder, CJ | 2 |
| Gilissen, LP | 1 |
| Jansen, JB | 1 |
| Reinshagen, M | 1 |
| Schütz, E | 1 |
| Armstrong, VW | 1 |
| Behrens, C | 1 |
| von Tirpitz, C | 1 |
| Stallmach, A | 1 |
| Herfarth, H | 1 |
| Stein, J | 1 |
| Bias, P | 1 |
| Adler, G | 1 |
| Shipkova, M | 1 |
| Kruis, W | 1 |
| Oellerich, M | 1 |
| von Ahsen, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL[NCT02046694] | Early Phase 1 | 34 participants (Actual) | Interventional | 2014-01-06 | Completed | ||
| Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System.[NCT00521950] | 853 participants (Actual) | Interventional | 2007-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for 6-methylthiopurine and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Chemical and Drug Induced Liver Injury; Cohort Studies | 2017 |
6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug | 2003 |
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
Topics: Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Crohn Disease; Dose-Response Relati | 2007 |
4 other studies available for 6-methylthiopurine and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
Topics: Adolescent; Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2014 |
Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease.
Topics: Adolescent; Azathioprine; Chemical and Drug Induced Liver Injury; Child; Crohn Disease; Female; Guan | 2014 |
Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides.
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Moni | 2008 |
Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
Topics: Antimetabolites, Antineoplastic; Azathioprine; Chemical and Drug Induced Liver Injury; Female; Human | 2012 |